Domača stran084990 • KOSDAQ
add
Helixmith Co Ltd
Prejšnji trg. dan.
2895,00 ₩
Dnevni razpon
2800,00 ₩ - 2985,00 ₩
Letni razpon
2115,00 ₩ - 4950,00 ₩
Tržna kapitalizacija
129,98 mrd. KRW
Povprečni obseg
193,34 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
KOSDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (KRW) | mar. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 930,47 mio. | 13,80 % |
Stroški poslovanja | 3,14 mrd. | −48,69 % |
Čisti dohodek | −1,53 mrd. | 71,47 % |
Čista dobičkovnost prihodkov | −164,30 | 74,93 % |
Earnings per share | — | — |
EBITDA | −2,32 mrd. | 50,15 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (KRW) | mar. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 81,43 mrd. | −8,21 % |
Skupna sredstva | 147,20 mrd. | −27,05 % |
Skupne obveznosti | 6,70 mrd. | −87,42 % |
Celoten lastniški kapital | 140,50 mrd. | — |
Shares outstanding | 46,05 mio. | — |
Razmerje P/B | 0,95 | — |
Donosnost sredstev | −4,83 % | — |
Donosnost kapitala | −5,05 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (KRW) | mar. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −1,53 mrd. | 71,47 % |
Denar iz dejavnosti | −1,78 mrd. | 69,42 % |
Denar iz naložb | 35,62 mrd. | 1.267,16 % |
Denar iz financiranja | −118,78 mio. | 99,41 % |
Neto sprememba denarnih sredstev | 34,01 mrd. | 217,30 % |
Prost denarni tok | −1,26 mrd. | 62,47 % |
Vizitka
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
Datum ustanovitve
nov. 1996
Spletno mesto
Zaposleni
33
